Related Experiment Videos
Aplastic anemia with circulating erythroblasts
1Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
International Journal of Hematology
|August 1, 1994
Summary
Circulating erythroblasts (Ebl) are not rare in aplastic anemia (AA) patients. Early AA treatment is crucial for Ebl-positive patients with severe cytopenia, ensuring positive outcomes.
Area of Science:
- Hematology
- Internal Medicine
- Oncology
Background:
- Erythroblasts (Ebl) in peripheral blood often suggest misdiagnosis in aplastic anemia (AA) suspicion.
- Delayed diagnosis and treatment in such cases can lead to severe consequences.
Purpose of the Study:
- To investigate the prevalence and clinical significance of circulating erythroblasts in untreated aplastic anemia patients.
- To determine if the presence of Ebl impacts diagnosis, treatment response, or prognosis in AA.
Main Methods:
- Examined 55 untreated aplastic anemia patients for circulating erythroblasts.
- Compared hematologic parameters and bone marrow morphology between Ebl-positive and Ebl-negative AA patients.
- Monitored treatment response and long-term outcomes.
Main Results:
- Seven out of 55 (12.7%) untreated AA patients had circulating erythroblasts (Ebl(+)).
- Ebl(+) AA patients exhibited typical AA features with no significant differences in age or hematologic parameters compared to Ebl-negative patients.
- All but one Ebl(+) AA patient responded well to AA therapy, with no disease transformation during follow-up.
Conclusions:
- Circulating erythroblasts are not uncommon in patients with otherwise typical aplastic anemia.
- Ebl(+) AA patients, especially those with severe cytopenia, should receive prompt aplastic anemia treatment.
- The presence of erythroblasts does not preclude a diagnosis of aplastic anemia or a positive treatment response.